Print Page  |  Close Window

Press Release

Avinger to Announce Fourth Quarter and Full Year 2016 Results on March 6, 2017

REDWOOD CITY, Calif. , Feb. 21, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease ("PAD"), today announced that it will release its financial results for the fourth quarter and full year 2016 after the close of trading on Monday, March 6, 2017 . The Company will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET .

Individuals interested in listening to the conference call may do so by dialing (844) 776-7820 for domestic callers or (661) 378-9536 for international callers and referencing Conference ID: 73906070. To listen to a live webcast, please visit the investor relations section of Avinger's website at: www.avinger.com.

A replay of the call will be available beginning March 6, 2017 at 4:30pm PT / 7:30pm ET through 4:30pm PT / 7:30pm ET on March 7, 2017 . To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference Conference ID: 73906070. The webcast will also be available on Avinger's website for one year following the completion of the call.

About Avinger, Inc.
Avinger, Inc. is a commercial-stage medical device company that designs, manufactures and sells image-guided, catheter-based systems for the treatment of patients with peripheral artery disease (PAD). PAD is characterized by a build-up of plaque in the arteries that supply blood to the legs and feet. The company's mission is to dramatically improve the treatment of vascular disease through the introduction of products based on its Lumivascular platform, the only intravascular image-guided system of therapeutic catheters available in this market. Avinger's current Lumivascular products include the Lightbox imaging console, the Ocelot family of catheters, which are designed to penetrate total arterial blockages, known as chronic total occlusions, or CTOs, and Pantheris, the first-ever image-guided atherectomy device, designed to precisely remove arterial plaque in PAD patients. For more information, please visit www.avinger.com.

Investor Contact: Matt Ferguson Avinger, Inc. (650) 241-7917 ir@avinger.com

Primary Logo

Avinger Inc